Directed Differentiation of hiPSCs into Corneal Endothelial
2026-05-15
This study establishes a robust, chemically defined protocol for differentiating human induced pluripotent stem cells (hiPSCs) into corneal endothelial cell-like cells by precisely modulating TGF-β and Wnt signaling. The approach addresses longstanding challenges in cell-based therapies for corneal endothelial dysfunction, offering a reproducible platform for translational research.
LGK-974: Precision PORCN Inhibition for Pancreatic Cancer Mo
2026-05-15
Explore LGK-974, a potent PORCN inhibitor, and its advanced application in dissecting Wnt-driven pancreatic cancer, including RNF43-mutant models. This article uniquely bridges molecular mechanism, protocol precision, and cutting-edge reference insights.
PKM2 Inhibitor (Compound 3k): Precision Tools for Cancer and
2026-05-14
PKM2 inhibitor (compound 3k) delivers next-generation precision in disrupting cancer cell glycolysis and modulating immune cell metabolism. This guide translates bench breakthroughs into actionable, data-driven workflows—empowering researchers to optimize oncology and immunometabolic assays with reproducible, selective PKM2 targeting.
PD98059: Selective MEK Inhibitor for MAPK/ERK Research
2026-05-14
PD98059 is a selective and reversible MEK inhibitor, widely used to dissect the MAPK/ERK pathway in cell signaling, apoptosis, and neuroprotection research. Its well-characterized inhibition profile and robust experimental documentation make it a benchmark tool for studies involving cell cycle arrest and apoptosis induction in leukemia and ischemia models.
Polybrene in Translational Research: Mechanism, Strategy, Im
2026-05-13
This article explores Polybrene (Hexadimethrine Bromide) 10 mg/mL as a cornerstone reagent in gene delivery, emphasizing mechanistic insights, experimental evidence, and strategic guidance for translational researchers. Integrating recent studies—including mutant p53 activation via small molecules—and scenario-driven best practices, it highlights Polybrene's pivotal role in enhancing viral transduction, lipid-mediated transfection, and assay reproducibility. The discussion situates APExBIO Polybrene as a differentiator in advanced biomedical workflows, bridging current literature with actionable protocol considerations and a forward-looking outlook.
CCK-8 Modulates Anxiety via Opioid Pathways in Morphine With
2026-05-13
This study demonstrates that cholecystokinin octapeptide (CCK-8) exerts anxiolytic effects in morphine-withdrawal rats by upregulating endogenous opioids via CCK1 receptor activation. The findings clarify a novel neuropeptide-mediated mechanism in opioid withdrawal and suggest new targets for intervention in opioid addiction and withdrawal-associated anxiety.
HyperScribe T7 High Yield RNA Synthesis Kit: Precision RNA W
2026-05-12
Unlock rapid, high-quality RNA synthesis for advanced research with the HyperScribe T7 High Yield RNA Synthesis Kit. This platform delivers reliable, scalable RNA production for applications including gene editing, RNA vaccine research, and functional genomics—backed by best-in-class yields and streamlined optimization.
Morphological Profiling Unveils HSBP7 in Titin Cardiomyopath
2026-05-12
This study pioneers high-content morphological profiling using the CARDIO assay to systematically investigate gene function in human cardiomyocytes. The research identifies HSBP7 as a novel modulator that can rescue contractile defects caused by titin mutations, offering new mechanistic insight into dilated cardiomyopathy and therapeutic target discovery.
ELP-Mediated p21 Peptide Delivery Suppresses Glioblastoma Pr
2026-05-11
This study demonstrates that elastin-like polypeptides (ELPs) can facilitate efficient intracellular delivery of a p21-derived peptide, leading to cell cycle arrest and reduced proliferation in diverse glioblastoma models. The findings highlight ELPs’ potential to overcome delivery barriers in brain tumors and reinforce the value of cytostatic approaches for hard-to-treat cancers.
Ceftolozane/Tazobactam: Advances in Gram-Negative Resistance
2026-05-11
The referenced study provides a comprehensive review of ceftolozane/tazobactam, a novel cephalosporin/β-lactamase inhibitor combination designed for treating complicated infections caused by resistant Gram-negative bacteria. Its key innovation is the enhanced activity against multidrug-resistant pathogens, especially Pseudomonas aeruginosa and ESBL-producing Enterobacteriaceae, with pharmacokinetic properties supporting robust clinical application.
Viperin Disrupts Coronavirus Replication via nsp8 Targeting
2026-05-10
This study reveals that Viperin, an interferon-induced enzyme, inhibits coronavirus replication not only by producing ddhCTP but also by directly binding to non-structural protein 8 (nsp8), disrupting the assembly of the viral replication-transcription complex. These findings broaden the mechanistic understanding of innate antiviral defenses and highlight conserved protein-protein interactions as potential targets for next-generation antiviral drug development.
Dissecting In Vitro Drug Response Metrics in Cancer Research
2026-05-09
Hannah R. Schwartz’s dissertation distinguishes between relative viability and fractional viability as critical, yet often conflated, measures in in vitro cancer drug response assessment. By clarifying their biological implications and analyzing how anti-cancer agents induce growth arrest and cell death with differing timing and magnitude, this work provides a more nuanced framework for evaluating drug efficacy and mechanistic action.
Proteoform-Specific Drug Targeting in Native Cell Signalling
2026-05-09
This study pioneers the direct characterization of proteoform-specific interactions in native membrane environments, revealing how post-translational modifications influence drug binding and efficacy. By leveraging advanced native top-down mass spectrometry, the research uncovers new complexities in targeting G protein-coupled receptors and highlights implications for selective phosphodiesterase inhibitor development.
IWP-L6: Precision Porcupine Inhibitor for Wnt Pathway Modula
2026-05-08
IWP-L6 from APExBIO delivers sub-nanomolar Porcupine inhibition, enabling high-fidelity Wnt pathway modulation for developmental, regenerative, and metabolic studies. With robust in vitro and in vivo validation, this tool empowers researchers to dissect Wnt-driven processes with clarity and reproducibility.
CUDC-907: Protocol and QC Guidance for Dual PI3K/HDAC Inhibi
2026-05-07
CUDC-907 offers researchers a dual PI3K and HDAC inhibitor for controlled in vitro studies targeting cancer cell signaling, cell cycle arrest, and apoptosis. This compound is intended strictly for research use in validated laboratory workflows and is not suitable for diagnostic, therapeutic, or clinical applications.
466 records 19/32 page Previous Next First page 上5页 1617181920 下5页 Last page